scanTK Kinase Selectivity & Profiling Assay Panel

130 assays - the world’s most complete collection of Tyrosine kinase assays

scanTK is the largest commercial panel of tyrosine kinases that includes a set of 130 both receptor and non-receptor kinases, plus important mutant forms. scanTK provides a comprehensive understanding of compound binding within the tyrosine kinase family and may serve to opportunistically identify unanticipated interactions leading to expanded therapeutic utility of compounds or as advanced starting points for new programs.

Panel Highlights and Benefits

  • The largest panel of receptor and non-receptor tyrosine kinase assays available
  • High-quality reproducible data
  • Rapid turnaround time
  • Dynamic dynamic range: can detect compounds with Kds <100 pM to >10 mM
  • Flexible -Standard and custom panels
  • Detection of multiple inhibitor types (e.g. type I, II & non-ATP competitive)
  • Economically priced
scanTK Kinase Dendrogram

Red circles (above) represent all kinases currently available in the KINOMEscan panel. Blue circles represent assays included in the scanTK panel.

Assay Sensitivity

Assay Sensitivity and Range

Binding constant (Kd) determinations for the indicated compounds against LOK demonstrate the broad range
of interaction affinities quantitatively measured using the KINOMEscan assay platform [click graph to enlarge].

Assay Quality

Z' Factor Analysis - one metric of assessing assay quality

Average Z' values and standard deviations were calculated for each kinase based on fourteen control wells per experiment in over 135 independent experiments spanning a period of sixteen months. Average Z' = 0.72 [click graph to enlarge].

 

Data Consistency


Profiling of the indicated compounds at 10uM in fourteen independent experiments against 442 kinases over a one year period. Correlation analysis was performed in a pair-wise comparison to calculate the correlation coefficient. The correlation coefficients range from 0.91 to 0.97 with an average of 0.95 [click graph to enlarge].

Detection of Type II Kinase Inhibitors

Activation State Specific Kinase Inhibitor Imatinib and phosphorylated ABL1

Binding constant (Kd) determinations were measured for interactions between imatinib, a known Type II inhibitor, and ABL preparations differentially phosphorylated on the A-loop.  Imatinib exhibited a 30-fold affinity preference for the non-phosphorylated state (Kd = 1.4 nM) relative to the phosphorylated state (Kd = 56 nM) [click graph to enlarge].